Phase Forward to Present at the 18th Annual Credit Suisse Healthcare Conference
More News related to PFWD
- Phase Forward CFO Chris Menard to Present at 2009 MIT Sloan CFO Summit
- Notable Analyst Rating Changes: ARO, CSX, PFWD, SIRI Upgraded; BRCD, BNI Downgraded
- Phase Forward (PFWD) Higher On UBS Upgrade
- UBS Upgrades Phase Forward (PFWD) to Buy
- Phase Forward Named Private Sector Company of the Year by Mass Technology Leadership Council
More News related to Press Releases
- Notable Late-Afternoon ETF Movers for 11/25: UNG, GDX, XRT Higher; UUP Lower
- Notable 52-Week High's and Low's: BMY, JCG, PBR, SLW, GOOG, INCY, NTAP, QADI, GOLD, BONT Higher; SPWRB Low
- Unusual 11 Mid-Day Movers 11/25: RTK, QADI, QBC, KBX Higher; BNHNA, DRAM, TBH, CWTR Lower
- Afternoon ETF Check: UNG, XRT, EWJ Up; VNM, RSX Down
- Notable Analyst Ratings Changes 11/25: EXXI, IWA, VPRT Upgraded; BNHN, NRG, GTE Downgraded
WALTHAM, Mass.--(BUSINESS WIRE)-- Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its senior vice president and chief financial officer, Chris Menard, and senior vice president of integration and product strategy, Martin Young, will present at the 18th Annual Credit Suisse Healthcare Conference at the Arizona Biltmore Hotel in Phoenix, Arizona.
The Phase Forward presentation is scheduled for Wednesday, November 11, 2009 at 8:00 a.m. MT. The presentation will be webcast live and will be available by visiting the Investors section of the company's website at www.phaseforward.com. The webcast will be archived on the company's website for 30 days after the conference ends.
About Phase Forward
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com.
Source: Phase Forward
Related Categories
Press ReleasesStocks Mentioned
-0.25Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
